glycemic control
Procedureexogenous insulin
NCT Number: NCT01013662
Study of the lipid metabolism under glycemic control in septic patients who got an university 14 bed ICU.
Hypothesis: establish a relationship between lipid metabolism alterations and glycemic control or infusion of exogenous insulin
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
The investigators enrolled 69 consecutive patients with severe sepsis or septic shock and divided them in two different groups after randomization with sealed envelopes.
One group called intensive glycemic control with glycemic levels been between 80 to 110 mg/dl with exogenous insulin.
The other group called conventional glycemic control with glycemic levels been between 180 and 220 mg/dl.
Blood samples were collected at 0, 12, 24, 48 and 72 hours to measure HDL, LDL, Total cholesterol, free fatty acids and oxidized LDL.
Clinical data as creatinine, P/F ratio, bilirubins, platelets, lactate, arterial blood gasometry were either monitored.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
exogenous insulin
Time frame: 2 years
University of Sao Paulo
Other
Tight Glycemic Control and Sepsis Related Dyslipidemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07658014
Cardiovascular Diseases, Infections
Querétaro City, Querétaro, Mexico
View Trial DetailsNCT05900284
Acute Kidney Injury, Female Urogenital Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT05194189
Infections, Inflammation
Guanzhou, Guangdong, China
View Trial DetailsNCT07565649
Infections, Inflammation
Pamplona, Navarre, Spain
View Trial Details